Novavax appoints new senior vice president of commercial operations
Trizzino, who previously served as the company's senior vice president of business development from 2010 to 2011, will be responsible for the developing and implementing the commercialization strategy in support of the company's product candidates.
"With our success in product development in the clinic, and our expectations around future development plans, we recognize the need to maximize the value of our vaccine candidates through a fully developed commercialization strategy," Stan Erck, the president and CEO of Novavax, said. "John's knowledge of the vaccine industry, with specific experience in vaccine commercialization, distribution and reimbursement, provide us with the insight needed to develop that commercialization strategy. We are very excited to have John return to the team and look forward to his contributions to our success."
Novavax focuses on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants to address a broad range of infectious diseases. The company's product candidates include respiratory syncytial virus, quadrivalent seasonal influenza and pandemic influenza vaccine candidates.
"Novavax is at an important milestone in the development of its RSV, seasonal influenza and pandemic influenza vaccines," Trizzino said. "As these vaccine candidates move into the later stages of clinical development it is the right time to develop a commercialization strategy to ensure a successful path to market. Novavax' RSV vaccine has the opportunity to be the first vaccine to address the significant burden of this disease in both the very old and the very young. I am looking forward to working with the Novavax team again in pursuit of these and the other vaccine candidates in its pipeline."
Trizzino most recently served as the CEO of Immunovaccine.